恩格列净通过代谢重编程调节免疫性血小板减少症中CD4+ T细胞分化
免疫性血小板减少症(ITP)中CD4+ T细胞亚群失衡参与发病,T细胞代谢从氧化磷酸化向糖酵解偏移。恩格列净可抑制Th1和Th17细胞群体、增加Tregs,似乎通过抑制mTOR信号通路调节CD4+ T细胞。作者提出恩格列净可作为ITP的潜在治疗选择。
要点
- ITP中CD4+ T细胞代谢从氧化磷酸化向糖酵解偏移。
- 恩格列净抑制Th1和Th17细胞群体并增加Tregs。
- 恩格列净似乎通过抑制mTOR信号通路调节CD4+ T细胞。
核心结论
- 作者提出恩格列净可通过调节CD4+ T细胞代谢重编程作为ITP的潜在治疗选择。
研究设计与样本
- 基础研究,探索恩格列净对ITP中CD4+ T细胞分化的影响。
主要发现
- ITP中T细胞代谢从氧化磷酸化向糖酵解偏移。
- CD4+ T细胞糖酵解增加导致CD4+ T细胞群体失衡。
- 恩格列净抑制Th1和Th17细胞群体并增加Tregs,影响CD4+ T细胞亚群分化。
- 恩格列净似乎通过抑制mTOR信号通路调节CD4+ T细胞。
临床怎么用
- 作者提出恩格列净可作为ITP的潜在治疗选择,通过调节CD4+ T细胞代谢重编程发挥作用。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Immune thrombocytopenia (ITP) is an acquired autoimmune disease, in which the imbalance of CD4+ T cell subsets play a key role in the pathogenesis. Since T cells highly depend on metabolism for their function, we hypothesized that T cell dysfunction may be due to intracellular metabolic reprogramming. We found that in ITP, T cell metabolism shifts from oxidative phosphorylation to glycolysis. Empagliflozin, a sodium-glucose cotransporter 2 inhibitor, has shown regulatory metabolic effects on proximal tubular epithelial cells and cardiac cells beyond glucose lowering. However, the effects of empagliflozin on T cells remain unknown. To further investigate the metabolic dysfunction of CD4+ T cells in ITP, we explored the effect of empagliflozin on CD4+ T-cell differentiation in ITP. Our results are the first to show that increased glycolysis in CD4+ T cells resulted in an unbalanced CD4+ T-cell population. Furthermore, empagliflozin can affect the differentiation of CD4+ T-cell subsets by inhibiting Th1 and Th17 cell populations while increasing Tregs. Empagliflozin appears to regulate CD4+ T cells through inhibiting the mTOR signal pathway. Considering these results, we propose that empagliflozin could be used as a potential therapeutic option for ITP by modulating metabolic reprogramming in CD4+ T cells.
引用
- Qin J, Liu Q, Liu A, et al. Empagliflozin modulates CD4+ T-cell differentiation via metabolic reprogramming in immune thrombocytopenia. Br J Haematol. 2022. PMID: 35675486. doi:10.1111/bjh.18293
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。